Скачать или смотреть Cambrex Boosts US Drug Manufacturing with $120M Investment

Cambrex, a leading global CDMO, is investing $120 million to expand its U.S. manufacturing capabilities, particularly at its Charles City, Iowa facility, which will see a 40% increase in production capacity to nearly one million liters. The investment supports Cambrex’s mission to strengthen domestic API production, enhance U.S. drug supply chain resilience, and advance its position in the growing peptide therapeutics market.

CEO Thomas Loewald highlighted the move as part of a broader reshoring trend in pharmaceutical manufacturing, emphasizing the importance of local API production for national supply security.

This initiative builds on Cambrex’s recent expansions, including:

2022: Boosted highly potent API and large-scale capacity in Iowa.

2023: Opened new labs and mid-scale manufacturing in High Point, NC.

2025: Expanding peptide therapeutics GMP manufacturing in Waltham, MA.

Together, these efforts underscore Cambrex’s long-term commitment to U.S.-based innovation, infrastructure investment, and reliable API supply.

For further information visit: https://www.chemanalyst.com/

Follow us on LinkedIn:   / chemanalyst  

For business inquiries: [email protected]

#Cambrex #CDMO #therapeuticsmarket #pharmaceutical #investment